Paradigm Biopharmaceuticals (ASX:PAR) Other Stockholders Equity: A$-0.00 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
26 GF Score
Price A$0.18
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Other Stockholders Equity?

Paradigm Biopharmaceuticals ASX:PAR +2.94% 26 Other Stockholders Equity is A$-0.00 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's Other Stockholders Equity for the quarter that ended in Dec. 2025 was A$-0.00 Mil.

Paradigm Biopharmaceuticals's quarterly Other Stockholders Equity increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil) but then declined from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$-0.00 Mil).

Paradigm Biopharmaceuticals's annual Other Stockholders Equity declined from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$-0.00 Mil) but then increased from Jun. 2024 (A$-0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Paradigm Biopharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Other Stockholders Equity Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 0.00

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 -0.00
ASX:PAR
26GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of A$-0.00 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Other Stockholders Equity of A$-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Other Stockholders Equity too high?
Paradigm Biopharmaceuticals' current Other Stockholders Equity is A$-0.00 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Other Stockholders Equity compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Other Stockholders Equity of A$-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Other Stockholders Equity is A$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Other Stockholders Equity of A$-0.00 Mil. The current Other Stockholders Equity is A$-0.00 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Other Stockholders Equity is A$-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
26GF Score

Get the complete analysis for ASX:PAR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price